Tony McHale standing in his garden, smiling.

Help every man with prostate cancer

Give the gift of research to help every man with prostate cancer live longer, healthier lives.

Donate now

Tony McHale (pictured above) discovered he had an alteration in the BRCA2 gene at the age of 61, putting him at a much higher risk of developing prostate cancer. Shortly after, Tony joined the IMPACT study at the ICR, which investigated whether regular screening would lead to earlier diagnosis of aggressive forms of the disease. Around 18 months later, the screening revealed Tony had prostate cancer. 

"Being involved in the IMPACT study saved my life. If I hadn't taken part, I'd never have known I had prostate cancer. As far as I was aware, I didn't have any symptoms – and the sooner the disease is detected and treated, the better the chances are of survival." – Tony

Godfrey's prostate cancer story

 

DJ and music promoter, Godfrey Fletcher, found out he had prostate cancer in 2015 at the age of 47, shortly after his father had also been diagnosed.

"I was so lucky that my cancer was picked up at a very early stage. I was young and fit, with no symptoms. A year after my treatment finished, I was told it had been successful. My dad wasn't so fortunate. He was diagnosed with advanced prostate cancer and passed away at 80. His experience, and mine, showed me the importance of early diagnosis."

Why we need more research into prostate cancer

We're proud of the research advances we've made over the last 20 years. Our scientists discovered the drug abiraterone; identified genetic variants that influence risk of developing the disease; and pioneered new, more precise forms of radiotherapy. But despite our research advances, some prostate cancers remain difficult to treat. This includes those diagnosed at a later stage and those more aggressive tumours, which can spread quickly and evolve to resist treatment.

That's why we urgently need better ways to detect prostate cancer earlier, predict drug resistance, and develop smarter, more personalised treatments. Your gift will help our world-leading researchers unravel the complexity of prostate cancer, to give men precise and personalised care with the right treatments at the right time, to live longer and healthier lives.

Professor Eeles's goal is to develop new tests that could be used in prostate cancer screening, helping to identify men at a higher risk. Her team showed that a simple saliva test, carried out at home, was more accurate at identifying future risk of prostate cancer for some men than the current standard blood test. 

Building on this success, they recently launched a major new study to find out whether an improved version of this test – now suitable for more diverse groups, including Black men and younger men – can help detect more cancers earlier in men at higher risk. 

Tackling drug resistance

Our research underpinned the development of olaparib, a drug that revolutionised treatment for people with BRCA-related cancers. In a recent study, Professor Johann de Bono's team showed that changes which can be spotted with a simple blood test can reveal how long a prostate cancer patient will respond to olaparib. 

The ability to predict when – and how – patients will stop responding to olaparib could help doctors personalise treatment, and in the future, guide the development of new drugs to outsmart resistance – keeping us one step ahead of prostate cancer.

Professor Johann de Bono in the laboratory, smiling.

Creating smarter, kinder treatments for every man

Our scientists are at the forefront of precision cancer medicine – developing more effective treatments with fewer side effects.

Laboratory studies co-led by Dr Adam Sharp and Professor Johann de Bono showed that NXP800 – a new drug which targets a ‘master switch’ that cancer cells hijack to support their growth – slowed prostate cancer cell growth. This innovative drug could potentially also benefit men with advanced prostate cancer that has stopped responding to standard hormone therapy.

A study co-led by Professor Emma Hall has found that men with intermediate-risk, localised prostate cancer can be treated just as effectively with five sessions of higher-dose radiation therapy as with several weeks of standard treatment. Using stereotactic body radiotherapy (SBRT), which targets tumours with pinpoint accuracy, patients can receive a highly effective treatment with far fewer hospital visits. 

A study co-led by Professor Nick James has shown that a new artificial intelligence (AI) test can select which men with high-risk prostate cancer that has not spread will require the life-extending drug abiraterone. In the STAMPEDE trial, the team found that three out of four men could be spared unnecessary treatment, making the drug – discovered by our scientists – more affordable for the NHS.

Your gift can help every man with prostate cancer live longer, healthier lives

Help someone's dad, grandad, brother, uncle, partner, or friend survive prostate cancer. Your support will help fund life-saving research – so that every man can spend more precious time with their loved ones.

Make a donation

Your gift of research can help transform the lives of every man with prostate cancer.
With GiftAid you'll also be able to add 25% at no extra cost to you

Please choose a donation amount.

Your gift of research can help transform the lives of every man with prostate cancer.
With GiftAid you'll also be able to add 25% at no extra cost to you

Please choose a donation amount.

 Related news and blogs

05/03/14 - by

Most of us know our blood group. It’s taken early in our life and stored in our patient record, and it’s important that should we ever need a blood transfusion, doctors know what it is. Our blood type is based on whether one, both or neither of two sugar molecules, referred to as A and B, are present on the surface of our red blood cells. There’s A, B, AB and the most common type, 0, which means neither are present.

But what if we could use a similar system to classify our gut bacteria? And what if people with different ‘gut groups’ could have different medical needs?

Communities of bacteria and other organisms, including viruses, have evolved in tandem with us over millions of years. Although they account for only a tiny fraction of our weight, there are about 10 times more non-human cells than human cells in the human body, and a healthy ‘microbiota’ carries out functions from producing vitamin K to fighting off potentially harmful bacteria or viruses.

Although healthy people are known to have similar gut floras, evidence suggests that they may be divided into three groups according to their intestinal bacteria, called ‘enterotypes’. One is enriched in a type of bacteria called Bacteriodes, the second in Prevotella, and the third in Ruminococcus.

Some gut bacteria are known to be relevant in cancer – for example, the link between Helicobacter pylori and stomach cancer has long been known. Some bacteria such as Roseburia or Eubacterium seem to have beneficial effects by producing molecules such as butyrate, which may protect us from harmful side-effects of radiotherapy.Helicobacteria

Gut bacteria and radiotherapy

This week saw the publication of an article in The Lancet Oncology from a team led by Professor David Dearnaley and Dr Jervoise Andreyev, here at The Institute of Cancer Research in London and The Royal Marsden NHS Foundation Trust. The article applies principles from the study of the microbiome – one of the most cutting-edge areas of current science – to cancer care.

Professor Dearnaley, an expert in radiotherapy, is interested in reducing the side-effects it can cause in some patients. Among these side-effects, radiotherapy to the abdomen can cause gut problems, which sometimes arise soon after treatment, but can also take longer to develop. Professor Dearnaley’s team argue in the Lancet Oncology article that these gut problems show a remarkable similarity to inflammatory bowel disease, which has well-known links to disturbances in gut flora. It seems that bowel problems after radiotherapy may be caused at least in part by their effect on the bacteria that live there.

Bacterial treatments?

A fascinating question – which our scientists aim to explore – is whether profiling the gut ecosystem could help inform patient care. The ultimate aim would be to effectively manipulate the gut ecosystem as an actual treatment for intestinal problems after radiotherapy. Beneficially altering the make-up of our gut flora is still an emerging discipline but, for example, a study has already shown that transplanting faeces from healthy donors into patients can effectively treat recurrent Clostridium difficile infection which does not respond well to antibiotics. This treatment method has also been shown to have an effect in inflammatory diseases of the bowel unrelated to infections.

The terms ‘microbiota’ and ‘microbiome’ have only been around since the turn of the 21st Century, and the detailed study of the gut flora in relation to human health is relatively new. The work of researchers here at the ICR and The Royal Marsden could represent the first steps towards personalised cancer treatment based on the ecosystem of microscopic inhabitants of our bodies.

For further reading on recent developments in our understanding of the effect of the microbiome on human health, see this briefing from the Medical Research Council.

---

Image credit B0004847 David Gregory&Debbie Marshall, Wellcome Images: Creative Commons by-nc-nd 2.0 UK: England & Wales. The image is a scanning electron micrograph of a colony of Helicobacter bacteria.